Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition. Most patients, however, harbor residual leukemia cells, and disease recurrence usually occurs when imatinib is discontinued. Although various mechanisms to explain leukemia cell persistence have been proposed, the critical question from a therapeutic standpoint--whether disease persistence is BCR-ABL dependent or independent--has not been answered. Here, we report that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. Imatinib inhibited BCR-ABL activity to the same degree in all stem (CD34+CD38-, CD133+) and progenitor (CD34+CD38+) cells and in quiescent and cycling progenitors from newly diagnosed CML patients. Although short-term in vitro imatinib treatment reduced the expansion of CML stem/progenitors, cytokine support permitted growth and survival in the absence of BCR-ABL activity that was comparable to that of normal stem/progenitor counterparts. Our findings suggest that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR-ABL will not eliminate CML stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Even potent TKIs are unable to eradicate CML-LSCs,6,7 which are the main culprit of disease relapse upon TKI discontinuation.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ki-67 protein: From the known and the unknown
Scholzen, T., & Gerdes, J. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200003)182:3<311::aid-jcp1>3.0.co;2-9 · Cited by 4,646 · cited 1×
“To clarify this question, we analyzed BCR-ABL activity in imatinib-treated quiescent CML cells using Ki-67 negativity as a marker of quiescence (37).”
MethodFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 3×
“Newly diagnosed patients with chronic phase CML have an almost 90% chance of being alive at 60 months after diagnosis (2).”
BackgroundSelf-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280 · cited 2×
“Enhanced expression of the drug efflux pumps breast cancer resistance protein (10) and P-glycoprotein (11) in CML stem cells may reduce sensitivity to imatinib by lowering intracellular imatinib concentrations (12–15).”
BackgroundAC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
The molecular biology of chronic myeloid leukemia
Deininger, M. W. N., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.10.3343 · Cited by 1,667 · cited 2×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundSelf-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 1×
“Introduction Chronic myeloid leukemia (CML) originates in a HSC with the reciprocal translocation t(9;22) (1).”
BackgroundHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218 · cited 4×
“Those whose disease is undetectable by RT-PCR usually experience recurrence of active leukemia when imatinib therapy is discontinued (4, 5), which indicates that leukemic cells persist in most patients even when the disease burden is reduced below detectable limits.”
BackgroundInfluentialGraham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181 · cited 6×
“In accord with previous reports (19), we observed that primitive noncycling BCR-ABL–positive cells”
BackgroundResultInfluential
Cited by
Items 501–600 of 799
Bono, S., Sbarba, P. D., & Lulli, M. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.01.038 · Cited by 10
Moisoiu, V., Teodorescu, P., Parajdi, L. G., Paşca, S., Zdrenghea, M., Dima, D. M., Precup, R., Tomuleasa, C., & Soverini, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00863 · Cited by 10
“Several studies brought strong evidence for the fact that TKI therapy does not directly eliminate CML stem cells (84, 85).”
BackgroundTadele, D. S., Robertson, J. M., Crispin, R., Herrera, M. C., Chlubnová, M., Piechaczyk, L., Durán, P. A., Singh, S. K., Gedde‐Dahl, T., Fløisand, Y., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015285 · Cited by 9
“LSCs do not require BCR–Abl activity and are therefore resistant to imatinib (9).”
BackgroundEarly epigenetic cancer decisions
Martín‐Lorenzo, A., González‐Herrero, I., Rodríguez-Hernández, G., García‐Ramírez, I., Vicente‐Dueñas, C., & Sánchez-García, I. (2014) · Biological Chemistry · doi:10.1515/hsz-2014-0185 · Cited by 9
“CML is widely accepted to be a stem-cell disorder where the specific BCR-ABL inhibitor STI571 is able to eliminate the BCR-ABL-expressing differentiated cells that constitute the bulk of the tumour, but it cannot eliminate BCR-ABL-expressing CSCs (Chomel et al., 2011; Chu et al., 2011; Corbin et al., 2011; Hamilton et…”
BackgroundInfluentialYang, P., Shen, H., Tang, S., Huang, Z., Hao, Y., Luo, Z., Zhou, F., Wang, T., & Feng, W. (2018) · Microchimica Acta · doi:10.1007/s00604-018-2940-1 · Cited by 9
Khamidullina, A. I., Yastrebova, M. A., Bruter, A. V., Nuzhina, J., Vorobyeva, N. E., Khrustaleva, A. M., Varlamova, E. A., Tyakht, A., Abramenko, Y. E., Ivanova, E. S., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02339-6 · Cited by 8
“The main genetic marker of CML is the Philadelphia chromosome generated by translocation t(9;22)(q34;q11).”
InfluentialHuang, G., Yin, Z., Wang, X., Wen, Z., Su, R. J., Li, C., Liu, Y., Yang, J., Hu, H., Nie, H., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154918 · Cited by 8
BCAT1 contributes to the development of TKI-resistant CML
Jiang, Y., Zhang, D., He, X., Chen, C., Xie, L., Liu, L., Yu, Z., Zhang, Y., Zheng, J., & Huang, D. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01003-y · Cited by 8
“Additionally, increasing evidence shows that a small population of leukemia cells, termed leukemia-initiating cells (LICs), may contribute to drug resistance or leukemia relapse [8, 9].”
Minami, Y., Abe, A., Minami, M., KITAMURA, K., Hiraga, J., Mizuno, S., Ymamoto, K., Sawa, M., Inagaki, Y., Miyamura, K., et al. (2012) · Leukemia · doi:10.1038/leu.2012.73 · Cited by 8
Developing therapeutic approaches for chronic myeloid leukemia: a review
Kumar, V., Jyotirmayee, & Verma, M. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04576-0 · Cited by 10
“Moreover, data available in the literature confirm that LSCs’ survival is BCR::ABL independent [15].”
BackgroundNaka, K., Hoshii, T., Tadokoro, Y., & Hirao, A. (2011) · Pathology International · doi:10.1111/j.1440-1827.2011.02688.x · Cited by 10
Practical Monitoring of Chronic Myelogenous Leukemia: When to Change Treatment
Saglio, G. N., & Fava, C. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0011 · Cited by 8
Leo, E., Mancini, M., Castagnetti, F., Gugliotta, G., Santucci, M. A., & Martinelli, G. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25010 · Cited by 8
“…does not depend from BCR-ABL1 TK for proliferation and survival and is resistant in vitro to IM and the second generation TK inhibitors nilotinib and dasatinib [Graham et al., 2002; Copland et al., 2006; Jorgensen et al., 2007; Lemoli et al., 2009; Corbin et al., 2011; Hamilton et al., 2012].”
BackgroundClinical and biological predictors of outcome following relapse of CML post-allo-SCT
Jain, N. A., Ito, S., Tian, X., Kurlander, R. J., Battiwalla, M., Lu, K. Y., Savani, B. N., Malkovska, V., Rezvani, K., Le, R., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.249 · Cited by 8
Leukemia stem cells: Old concepts and new perspectives
Mariani, S. A., & Calabretta, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.06.003 · Cited by 8
“A consensus has now emerged that BCR/ABL tyrosine kinase activity is suppressed by treatment of CML stem cells with TKIs and yet these cells remain “insensitive” in that they survive and eventually proliferate, although at the slow pace of stem cell (Corbin et al, 2011; Hamilton et al, 2012).”
BackgroundLiu, M.-Y., Wang, W., Liao, F., Wu, Q., Lin, X., Chen, Y., Cheng, L., Jin, X., & Zhu, J. (2016) · Cell Biology International · doi:10.1002/cbin.10686 · Cited by 8
“Consistent with previous report, IM was not capable to induce apoptosis of CML LSCs even at a high concentration (Corbin et al., 2011).”
BackgroundResultCayssials, É., Tartarin, F., Guilhot, J., Sorel, N., Chomel, J., Leleu, X. P., & Guilhot, F. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1357178 · Cited by 8
“However, there is a persistent residual disease that implies longterm maintenance with the cohort of adverse events related to long-term exposure to therapy [2,3].”
BackgroundEmerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia
Kavanagh, S., Nee, A., & Lipton, J. H. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1445717 · Cited by 8
“While the bulk of leukemic cells are dependent on BCR-ABL signaling for survival, a proportion of the malignant stem cell population is less ‘addicted’ and is able to survive despite long-term TKI therapy [61].”
BackgroundVÎnturiȘ, E. G. P., & Găman, A. M. (2020) · PubMed Central · doi:10.12865/chsj.46.01.04 · Cited by 8
“First generation (imatinib), second generation (dasatinib, nilotinib, bosutinib) and third generation (ponatinib-for CML presenting T315I mutation) TKIs (tyrosine kinase inhibitors) are the current standard treatment in CML and they frequently induce major molecular response [7].”
BackgroundImpact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia
Pokorny, R., Stenehjem, D. D., & Gilreath, J. A. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221077254 · Cited by 8
Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell–derived hematopoiesis model
Melkus, M. W., Griscelli, A. B., Valogne, Y., Flamant, S., Chomel, J., Sorel, N., Bonnet, M., Deininger, M. W., Mitjavila‐Garcia, M. T., & Turhan, A. G. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.12.004 · Cited by 8
Self-citationSchnetzke, U., Fischer, M., Frietsch, J. J., Finkensieper, A., Clement, J. H., Hochhaus, A., & Rosée, P. G. L. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21091 · Cited by 8
“Recently, it has been shown that primitive CML progenitor cells have the ability of BCR-ABL independent survival in the presence of TKIs indicating that the leukemic stem cells are the origin of molecular resistance (25).”
BackgroundMancini, M., De Santis, S., Monaldi, C., Castagnetti, F., Lonetti, A., Bruno, S., Dan, E., Sinigaglia, B., Rosti, G., Cavo, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901132 · Cited by 7
“Moreover, it has been extensively demonstrated that CML LSCs are not dependent on BCR::ABL1 for their survival (35, 36).”
BackgroundJo, T., Saburi, Y., Masunari, T., Noguchi, K., Sakai, T., Taguchi, J., Ohtsuka, E., Sezaki, N., Kubota‐Koketsu, R., & Kiguchi, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062713 · Cited by 7
“TKIs are known to effectively suppress proliferating leukemic cells but fail to eradicate quiescent CML stem cells [35]; thus, long-term immune surveillance is crucial for maintaining remission after TKI discontinuation.”
Chen, D., Lin, X., Zou, W., He, Q., Wei, F., Pan, J., Liu, C., & Jin, Y. (2024) · Oncogene · doi:10.1038/s41388-024-03215-w · Cited by 7
“Previous studies demonstrate that LSCs are insensitive to TKIs treatment because of their survival is BCR-ABL kinase independent [5 – 7].”
Pk, D., & Majumder, D. (2015) · Journal of Computational Systems Biology · doi:10.15744/2455-7625.1.104 · Cited by 7
Yuda, J., Odawara, J., Minami, M., Muta, T., Kohno, K., Tanimoto, K., Eto, T., Shima, T., Kikushige, Y., Kato, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14424 · Cited by 7
Rattigan, K. M., Zarou, M. M., Brabcová, Z., Prasad, B., Zerbst, D., Sarnello, D., Kalkman, E. R., Ianniciello, A., Scott, M. T., Dunn, K. M., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256279 · Cited by 8
“…has increased survival of patients in chronic phase (Druker et al , 2006), the failure of TKIs to eradicate LSCs that can re-establish disease (Corbin et al , 2011; Hamilton et al , 2012) means that the majority require life-long TKI treatment, which is associated with significant morbidities…”
BackgroundStem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia
Lahlil, R., Aries, A., Scrofani, M., Zanetti, C., Hennequin, D., & Drénou, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316671 · Cited by 7
“Indeed, it has been reported that primitive CML cells remain insensitive to IM despite the inhibition of BCR-ABL activity, and therapies that biochemically target this activity will not entirely eliminate CML stem cells, which may persist in patients despite prolonged treatment [6,7].”
BackgroundJacob, T., Agarwal, A., Ramunno-Johnson, D., O’Hare, T., Gönen, M., Tyner, J. W., Druker, B. J., & Vu, T. Q. (2016) · Scientific Reports · doi:10.1038/srep28163 · Cited by 7
Self-citationThan, H., Pomicter, A. D., Yan, D., Beaver, L. P., Eiring, A. M., Heaton, W. L., Senina, A. V., Clair, P. M., Shacham, S., Mason, C. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0708-1 · Cited by 7
Self-citationCombined effects on leukemia cell growth by targeting sphingosine kinase 1 and sirtuin 1 signaling
Li, Y., Gao, Y., Liang, B., Nie, W., Zhao, L., & Wang, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9392 · Cited by 8
“Although tyrosine kinase inhib‑ itor (TKI) therapy has successfully improved the long‑term survival rates of patients with CML (2), certain patients relapse due to TKI resistance (3).”
Eradicating residual chronic myeloid leukaemia: basic research lost in translation
Zhao, H., & Deininger, M. W. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00001-6 · Cited by 7
Self-citationA narrative review of imatinib-resistant gastrointestinal stromal tumors
Hayashi, Y., & Nguyen, V. T. T. (2021) · Gastrointestinal Stromal Tumor · doi:10.21037/gist-21-10 · Cited by 7
“Imatinib resistance has also been correlated with the recurrence of imatinib-resistant leukemia-initiating cells (LICs) in chronic myeloid leukemia (23).”
BackgroundShieh, M., Mitsuhashi, M., & Lilly, M. B. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6416 · Cited by 7
Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia
Stokłosa, T., Głodkowska‐Mrówka, E., Hoser, G., Kielak, M., Seferyńska, I., & Wlodarski, P. K. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.02.001 · Cited by 7
“It has also been postulated that residual disease is maintained by the small number of cells, identified as Lin–CD34þCD38 , that are insensitive to TKI and are referred to as leukemia stem cells or leukemia-initiating cells [30,31].”
BackgroundLi, Y., Deng, Z.-K., Din, B.-H., & Zhu, J. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.635859 · Cited by 7
Grimaudo, S., Meli, M., Cristina, A. D., Ferro, A., Pipitone, R. M., Romagnoli, R., Simoni, D., Dieli, F., & Tolomeo, M. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835e64a0 · Cited by 7
New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism
Naka, K. (2021) · International Journal of Hematology · doi:10.1007/s12185-021-03112-y · Cited by 9
Gu, R., Zhang, W., & Xu, D. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2044862 · Cited by 7
“Mutations in the Abl kinase domain and BcrAbl protein overexpression are the main mechanisms that contribute to TKI resistance (Perrotti et al. 2010; Corbin et al. 2011).”
BackgroundOnishi, I., Nakagawa, Y., Murayama, T., Hidaka, M., Yamamoto, K., Abe‐Suzuki, S., Abe, S., Kurata, M., & Kitagawa, M. (2014) · Pathology · doi:10.1097/pat.0000000000000180 · Cited by 7
Camacho, M. F., Peña, M., Toloza, M. J., Moiraghi, B., Enrico, A. I., Mariano, R., Negri, F., Pavlovsky, C., Ventriglia, V., Freitas, M. J., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01626-x · Cited by 9
“Some studies suggest that the LSC persistence, which can remain quiescent independently of BCR::ABL1 activity, may contribute to relapse [7, 18–20].”
Klag, T., Härtel, N., Erben, P., Schwaab, J., Schnetzke, U., Schenk, T., Hochhaus, A., & Rosée, P. G. L. (2012) · Leukemia · doi:10.1038/leu.2011.380 · Cited by 6
Xu, R., Liu, D., & Cowburn, D. (2012) · Molecular BioSystems · doi:10.1039/c2mb25051a · Cited by 6
Engineering a BCR-ABL–activated caspase for the selective elimination of leukemic cells
Kurokawa, M., Ito, T., Yang, C., Zhao, C., Macintyre, A. N., Rizzieri, D. A., Rathmell, J. C., Deininger, M. W., Reya, T., & Kornbluth, S. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206551110 · Cited by 6
“Additionally, because CML stem cells are innately resistant to TKIs, these drugs are not curative (5, 6).”
BackgroundSelf-citationEliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy
Carvajal, L. A., & Steidl, U. G. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.06.005 · Cited by 6
“In recent years, it has become increasingly clear that TKIs are not effective at killing the leukemic stem cells (LSCs) in CML, which are the malignant cells responsible for maintaining the disease (Chu et al., 2011; Corbin et al., 2011).”
BackgroundKim, N., Kim, M., Cho, Y., Chen, W., Lee, K., & Kim, H. S. (2020) · Cancers · doi:10.3390/cancers12071923 · Cited by 6
“Importantly, CD34+CD38− LSC are resistant to TKIs, regardless of BCR-ABL1 activation, accounting for disease persistence and relapse [14].”
BackgroundImmune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon‐alpha
Irani, Y., Hughes, A., Kok, C. H., Clarson, J., Yeung, D. T. O., Ross, D. M., Branford, S., Hughes, T. P., & Yong, A. S. M. (2023) · British Journal of Haematology · doi:10.1111/bjh.18984 · Cited by 6
Réa, D., Fodil, S., Lengliné, É., Raffoux, E., & Cayuela, J. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00728-9 · Cited by 8
Stem cell persistence in chronic myeloid leukemia
Deininger, M. W. (2012) · Leukemia Supplements · doi:10.1038/leusup.2012.24 · Cited by 7
Self-citationIkejiri, F., Honma, Y., Okada, T., Urano, T., & Suzumiya, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4350 · Cited by 6
“However, TKIs do not completely eliminate leukemia stem cells (LSCs), even in patients who achieve deep molecular responses (1-3).”
Farawela, H. M., Zawam, H. M., Al-Wakeel, H. A., El-Nagdy, M. H., Elrefaey, F. A., & Abdel-Rahman, H. A. (2019) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2018.1555854 · Cited by 6
Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit
Zhang, H., & Li, S. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0247 · Cited by 6
Tissue “Hypoxia” and the Maintenance of Leukemia Stem Cells
Sbarba, P. D., & Cheloni, G. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_6 · Cited by 6
Schoepf, A. M., Salcher, S., Hohn, V., Veider, F., Obexer, P., & Gust, R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000092 · Cited by 6
Xu, W., Wang, Z.-J., Li, K., Shen, Y., Lu, K., Lv, X., Wen, Y., & Jin, R. (2020) · Current Medical Science · doi:10.1007/s11596-020-2181-5 · Cited by 6
Filik, Y., Bauer, K., Hadzijusufovic, E., Haider, P., Greiner, G., Witzeneder, N., Hoermann, G., Hohensinner, P. J., Gleixner, K. V., Wojta, J., et al. (2021) · PubMed Central · Cited by 6
Sun, M., Li, S., Liu, Z., Ma, S., Liu, X., Meng, Q., Zheng, Y., & Chen, C. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107507 · Cited by 7
Sayın, S., Yıldırım, M., Erdoğdu, B., Kaplan, O., Koç, E., Bulduk, T., Cömert, M., Güney, M., Çelebier, M., & Aylı, M. (2025) · Metabolites · doi:10.3390/metabo15060376 · Cited by 6
Cancer Reversion Therapy: Prospects, Progress and Future Directions
Oisakede, E. O., Olawade, D. B., Bello, O. J., Analikwu, C. C., Egbon, E., Fapohunda, O., & Boussios, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47121049 · Cited by 6
“…of imatinib in CML likely involves not only inhibition of BCR-ABL kinase activity but also restoration of normal hematopoietic differentiation pathways [53], though a subset of patients experience disease relapse after treatment discontinuation, suggesting incomplete reversion in some cases.”
Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells
Naka, K. (2021) · Cancers · doi:10.3390/cancers13143434 · Cited by 5
“While mature CML cells actively proliferate due to BCR–ABL1-dependent signaling, CML stem cells are able to avoid proliferation and maintain quiescence in an oncogene-independent fashion [9].”
BackgroundCML stem cells and their interactions and adaptations to tyrosine kinase inhibitors
Gullaksen, S., Omsland, M., Brevik, M., Letzner, J., Haugstvedt, S., & Gjertsen, B. T. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2466817 · Cited by 7
Lineage Decision-Making within Normal Haematopoietic and Leukemic Stem Cells
Brown, G., Sánchez, L., & Sánchez-García, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062247 · Cited by 5
“The disease returns upon cessation of treatment due to the persistence of CML stem cells or the development of resistance [66].”
BackgroundSasaki, K., Fujiwara, T., Ochi, T., Ono, K., Kato, H., Onodera, K., Ichikawa, S., Fukuhara, N., Onishi, Y., Yokoyama, H., et al. (2022) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2022.j036 · Cited by 5
Battling Cancer: In the End What Matters the Most?
Lagasse, E. (2012) · Disruptive Science and Technology · doi:10.1089/dst.2012.0018 · Cited by 5
“21 This result fits well with the CSC theory where the CML stem cells are CSCs escaping the therapeutic agent while the progeny of the CML stem cells are susceptible to the same agent.”
Shah, M., Gallipoli, P., Lyons, J. F., Holyoake, T. L., & Jørgensen, H. G. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.01.005 · Cited by 5
Minimal Residual Disease Eradication in CML: Does It Really Matter?
Tantravahi, S. K., Guthula, R. S., O’Hare, T., & Deininger, M. W. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0409-7 · Cited by 5
Self-citationTrojani, A., Pungolino, E. M., Rossi, G., D’Adda, M., Lodola, M., Camillo, B. D., Perego, A., Turrini, M., Orlandi, E. M., Borin, L. M., et al. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170209 · Cited by 5
“According to in vitro studies, LSCs are insensitive to currently available TKIs [8,9].”
Pungolino, E. M., Rossi, G., Canal, G. D., Trojani, A., D’Adda, M., Perego, A., Orlandi, E. M., Lunghi, F., Turrini, M., Borin, L. M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25106 · Cited by 5
“Time-course and mechanisms of LPCs/LSCs clearance during TKI treatment have not been clearly established yet, although in vitro data suggests that quiescent LSCs are indeed not sensitive to BCR/ABL inhibition.(2,3) In vivo preliminary data suggest that residual CD341 Ph1 cells are very rarely detected in nilotinib-tre…”
BackgroundCellular and Molecular State of Myeloid Leukemia Stem Cells
Xie, X., Feng, M., Wang, Q., Wang, J., Yin, R. L., Li, Y., & Zhang, H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_2 · Cited by 6
Shvachko, L. P., Zavelevich, M. P., Df, G., & Телегеев, Г. Д. (2020) · Experimental Oncology · doi:10.32471/exp-oncology.2312-8852.vol-42-no-1.14285 · Cited by 5
Li, Y., Gu, J., Ding, Y., Gao, H., Li, Y., Sun, Y., He, M. T., Zhang, W., Yin, J., Bai, C., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902651rr · Cited by 5
Overcoming Chronic Myeloid Leukemia Stem Cell Resistance to Imatinib by Also Targeting JAK2
Cogle, C. R. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt029 · Cited by 5
Massimino, M., Stella, S., Tirrò, E., Pennisi, M. S., Stagno, F., Vitale, S. R., Romano, C., Tomarchio, C., Parrinello, N. L., Manzella, L., et al. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s413825 · Cited by 4
Liang, Q., Liu, Z., Wu, Y. C., Zhu, H., & Yang, Y. (2024) · Acta Haematologica · doi:10.1159/000542153 · Cited by 6
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
Bica, V., Venafra, V., Massacci, G., Graziosi, S., Gualdi, S., Minnella, G., Sorà, F., Chiusolo, P., Brunetti, M. E., Napolitano, G., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02185-0 · Cited by 4
“BCR::ABL1 independent resistance mechanisms also play a crucial role in leukemia stem cells (LSCs), which are intrinsically resistant to TKI therapy and hinder long-term discontinuation, namely treatment-free-remission, in responder patients [11, 12].”
Baccarani, M., Gugliotta, G., Castagnetti, F., Soverini, S., & Rosti, G. (2016) · Hematologic malignancies · doi:10.1007/978-3-319-33198-0_4 · Cited by 6
Vitamin E in Chronic Myeloid Leukemia (CML) Prevention
Shvachko, L. P., Zavelevich, M. P., Df, G., & Телегеев, Г. Д. (2021) · Biochemistry · doi:10.5772/intechopen.96452 · Cited by 4
Imeri, J., Desterke, C., Marcoux, P. J., Chaker, D., Oudrhiri, N., Fund, X., Faivre, J., Griscelli, A. B., & Turhan, A. G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1117781 · Cited by 4
“Indeed, TKI treatment is unable to eliminate quiescent stem cell fraction (7), and the survival of LSC is independent on BCR::ABL TK activity (8).”
BackgroundPotential of siRNA Therapy in Chronic Myeloid Leukemia
Valencia‐Serna, J., Landry, B. K., Jiang, X., & Uludağ, H. (2014) · Fundamental biomedical technologies · doi:10.1007/978-94-017-8896-0_21 · Cited by 6
“These data indicate that even in the presence of Imatinib, especially in accelerated and advanced states of the disease, CML has progressed and evolved so these LSCs no longer require BCR-ABL activity to maintain their viability (Kumar et al. 2009; Zhang and Li 2013; Corbin et al. 2011; Muvarak et al. 2012), and anti-…”
BackgroundWoolfson, A., & Jiang, X. (2011) · InTech eBooks · doi:10.5772/29354 · Cited by 4
“not appear to be BCR-ABL tyrosine kinase activity dependent (Corbin et al., 2011).”
The Mechanisms of Therapy Resistance in Cancer Stem Cells
Chang, C.-H., & Rosen, J. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00015-2 · Cited by 5
Chen, C., Zhuang, Y., Chen, X., Chen, X., Li, D., Fan, Y., Xu, J., Chen, Y., & Wu, L. (2016) · Oncotarget · doi:10.18632/oncotarget.14324 · Cited by 4
“ABL kinase mutation and the insensitivity of CML LSCs to imatinib are major reasons for CML relapse [20-23].”
BackgroundBcl6 gene-silencing facilitates PMA-induced megakaryocyte differentiation in K562 cells
Eskandari, S., & Yazdanparast, R. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0395-5 · Cited by 4
“In that line, a recent in vivo study on megakaryopoiesis characterized the FoxO factors as negative regulators of murine megakaryocyte lineage specification during hematopoiesis (Cornejo et al. 2011).”
BackgroundJiang, L., Wang, H., Zhu, X., Liu, W., Zhou, S., Geng, Z., Xiao, Y., Zou, P., You, Y., Li, Q., et al. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0117 · Cited by 4
“However, TKIs do not target CML stem cells (LSCs) effectively, including the more potent second-and third-generation TKIs, and they approximate 60% of patients relapsing after discontinuation [8–11].”
Pungolino, E. M., D’Adda, M., Canal, G. D., Trojani, A., Perego, A., Elena, C., Lunghi, F., Turrini, M., Borin, L. M., Iurlo, A., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13680 · Cited by 4
Gugliotta, G., Castagnetti, F., Soverini, S., Rosti, G., & Baccarani, M. (2021) · Hematologic malignancies · doi:10.1007/978-3-030-71913-5_10 · Cited by 5
Chronic myeloid leukemia: where do we stand, where can we go?
Lewandowski, K. C., & Lewandowski, J. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.0012 · Cited by 4
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells
Philips, S. T., Hildenbrand, Z. L., Oravecz-Wilson, K. I., Foley, S. B., Mgbemena, V. E., & Ross, T. S. (2013) · Oncogene · doi:10.1038/onc.2013.484 · Cited by 4
SMYD3 Activates Fatty Acid β-Oxidation to Promote Self-Renewal of Leukemia Stem Cells
Zhou, M., Wu, Z., Wei, F., Duan, C., Lin, X., Zou, W., Liu, C., Pan, J., & Jin, Y. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2117 · Cited by 3
Bian, H., Zhou, C., Koyama, H., Gao, W., Bian, S., Cheng, T., Han, X., Tse, W. W., Liu, S., & Miron, A. (2025) · RNA NanoMed · doi:10.59566/isrnn.2025.0201e · Cited by 3
Kharas, M. G., & Daley, G. Q. (2010) · Genes & Cancer · doi:10.1177/1947601911407327 · Cited by 4
Žáčková, M., Lopotová, T., Ondráčková, Z., Kuželová, K., Klamová, H., & Moravcová, J. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.03.005 · Cited by 3
Wu, A., Ansari, A. S., Uludağ, H., & Jiang, X. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2022.04.002 · Cited by 3
Wang, X., Hou, Y., Lyu, Y., Zhou, J., Zhang, X., Hassani, M. A., Huang, D., Zhao, Z., Zhou, D. F., Xie, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109851 · Cited by 3
“14,49 Individuals Figure 5.”
Kusaba, K., Watanabe, T., Kidoguchi, K., Yamamoto, Y., Tomoda, A., Hoshiko, T., Kojima, N., Nakata, S., & Kimura, S. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011093 · Cited by 3
“This means that disease recurrence usually occurs after TKI discontinuation because surviving CML leukemic stem cells (LSCs) are BCR::ABL kinase-independent and insensitive to TKIs [3,4].”
BackgroundGPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells
Wang, J., Wang, J., Lin, Z.-L., Xu, N., Zhang, L., Liu, J., Gao, R., & Long, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02502-z · Cited by 3
“CMLleukemia stem cells (LSCs) can be considered as drug-resistant cells, which is BCR/ABL kinase-independent [3].”
What Does a Deep Molecular Response Signify?
Politi, J., & Shah, N. P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.8307 · Cited by 3
“It has been postulated that CML stem cells do not require BCR-ABL for survival.(30) A number of studies have implicated numerous different pathways as being critical for the survival of CML leukemic stem cells, including the sonic hedgehog pathway,(31) Alox5,(32) beta-catenin,(33) TGF -FOXO,(34) and SIRT1(35) as well…”
Cancer Stem Cells in Chronic Myelogenous Leukemia
Stefano, G. M. C. D. (2014) · Journal of Leukemia · doi:10.4172/2329-6917.1000159 · Cited by 3
“TKIs have been shown to block the kinase activity of BCRABL in LSCs [58,59]; however, the rate of apoptosis in LSCs upon TKI treatments is significantly lower than in progenitors.”
BackgroundИнтерлейкин-33: друг или враг в борьбе против опухоли?
Gorbacheva, A. M., & Mitkin, N. A. (2019) · Molecular Biology · doi:10.1134/s0026898419050069 · Cited by 5
Metadata
- Authors
- Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Oregon Health & Science University (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2011-01-04
- Volume
- 121
- Issue
- 1
- Pages
- 396-409
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3007128
- OpenAlex
- W2122224021
- Cited by
- 765
- References
- 47
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 32 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 57 · 2019: 51 · 2018: 47 · 2017: 66 · 2016: 53 · 2015: 51 · 2014: 67 · 2013: 76 · 2012: 66
- FWCI
- 36.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- T.J. Martell Foundation
- Leukemia and Lymphoma Society
- National Heart, Lung, and Blood Institute (R01HL082978, HL082978-01)
- National Cancer Institute (R37CA065823)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, imatinib, BCR-ABL, leukemia stem cells, disease persistence, drug resistance, stem cell survival, CD34+CD38- cells, CD133, progenitor cells, oncogene addiction
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Models, Biological, Piperazines, Pyrimidines, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Cytokines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Cell Proliferation, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.